In the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial, NT-proBNP levels were measured in 5154 type 2 diabetes mellitus patients at baseline (15–90 days post ACS) and again after six months [17]. This evidence concerns the gene NPPB and diabetes mellitus.